We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
VOXZOGO (BioMarin Pharmaceutical Australia Pty Ltd)
Product name
VOXZOGO
Date registered
Evaluation commenced
Decision date
Approval time
117 (255 working days)
Active ingredients
vosoritide
Registration type
NCE/NBE
Indication
VOXZOGO is indicated for the treatment of achondroplasia in patients 2 years of age and older whose epiphyses are not closed. The diagnosis of achondroplasia should be confirmed by appropriate genetic testing.
Registration process
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.